Alnylam Pharmaceuticals (ALNY) Current Deferred Revenue (2009 - 2026)
Alnylam Pharmaceuticals' Current Deferred Revenue was $11.67 million in Q3 2026, up 359.2% from $2.54 million a year earlier and up 190.7% from the prior quarter.
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Current Deferred Revenue (2009 - 2026) Analysis & Trends
At the end of FY2025, Current Deferred Revenue at Alnylam Pharmaceuticals came in at $4.85 million, down 91.3% from FY2024.
- Current Deferred Revenue shows a five-year compound annual growth rate of -48.0% (FY2020 to FY2025).
- In earlier years, Current Deferred Revenue was $55.48 million in FY2024 (-46.0%), $102.75 million in FY2023 (+144.0%), $42.11 million in FY2022 (-71.8%) and $149.48 million in FY2021 (+17.5%).
- The Q3 2026 figure marks the highest quarterly Current Deferred Revenue since Q2 2025.
- Compared with a year earlier, Current Deferred Revenue was higher in 1 of the last eight quarters, with an average decline of 22.2%.
- The best year-over-year quarter for Current Deferred Revenue over five years was Q3 2026 (growth of 359.2%); the worst was Q3 2025 (a decline of 96.4%).
- Per Business Quant data, ALNY's Current Deferred Revenue in the three quarters before Q3 2026 was $4.01 million (Q2 2026), $3.21 million (Q1 2026) and $4.85 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn |
| 10 | Alnylam Pharmaceuticals | 20.30 Bn | 7.49 Bn | 1.10 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 11.67 Mn |
| Jun 30, 2026 | 4.01 Mn |
| Mar 31, 2026 | 3.21 Mn |
| Dec 31, 2025 | 4.85 Mn |
| Sep 30, 2025 | 2.54 Mn |
| Jun 30, 2025 | 15.08 Mn |
| Mar 31, 2025 | 28.16 Mn |
| Dec 31, 2024 | 55.48 Mn |
| Sep 30, 2024 | 71.03 Mn |
| Jun 30, 2024 | 69.01 Mn |
| Mar 31, 2024 | 76.85 Mn |
| Dec 31, 2023 | 102.75 Mn |
| Sep 30, 2023 | 77.14 Mn |
| Jun 30, 2023 | 54.64 Mn |
| Mar 31, 2023 | 35.79 Mn |
| Dec 31, 2022 | 42.11 Mn |
| Sep 30, 2022 | 144.21 Mn |
| Jun 30, 2022 | 114.29 Mn |
| Mar 31, 2022 | 131.84 Mn |
| Dec 31, 2021 | 149.48 Mn |
API Access
Alnylam Pharmaceuticals Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ALNY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "ALNY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ALNY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();